4//SEC Filing
Ellis Andrea 4
Accession 0000950170-25-054883
CIK 0001743881other
Filed
Apr 15, 8:00 PM ET
Accepted
Apr 16, 5:39 PM ET
Size
8.4 KB
Accession
0000950170-25-054883
Insider Transaction Report
Form 4
Ellis Andrea
Director
Transactions
- Exercise/Conversion
Stock Option (right to buy)
2025-04-14−10,000→ 64,921 totalExercise: $8.45Exp: 2032-06-22→ Common Stock (10,000 underlying) - Sale
Common Stock
2025-04-14$35.00/sh−10,000$350,000→ 12,000 total - Exercise/Conversion
Common Stock
2025-04-14$8.45/sh+10,000$84,500→ 22,000 total
Footnotes (2)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 30, 2024.
- [F2]The stock option vests and becomes exercisable in three annual installments starting on June 22, 2023 and ending on June 22, 2025, subject to the Reporting Person's continued service on the Issuer's Board of Directors.
Documents
Issuer
BridgeBio Pharma, Inc.
CIK 0001743881
Entity typeother
Related Parties
1- filerCIK 0001877680
Filing Metadata
- Form type
- 4
- Filed
- Apr 15, 8:00 PM ET
- Accepted
- Apr 16, 5:39 PM ET
- Size
- 8.4 KB